IBDEI0VE ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15525,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15525,1,3,0)
 ;;=3^605.
 ;;^UTILITY(U,$J,358.3,15525,1,4,0)
 ;;=4^PHIMOSIS
 ;;^UTILITY(U,$J,358.3,15525,2)
 ;;=^104159
 ;;^UTILITY(U,$J,358.3,15526,0)
 ;;=185.^^95^945^17
 ;;^UTILITY(U,$J,358.3,15526,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15526,1,3,0)
 ;;=3^185.
 ;;^UTILITY(U,$J,358.3,15526,1,4,0)
 ;;=4^PROSTATE CANCER
 ;;^UTILITY(U,$J,358.3,15526,2)
 ;;=^99481
 ;;^UTILITY(U,$J,358.3,15527,0)
 ;;=600.10^^95^945^18
 ;;^UTILITY(U,$J,358.3,15527,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15527,1,3,0)
 ;;=3^600.10
 ;;^UTILITY(U,$J,358.3,15527,1,4,0)
 ;;=4^PROSTATE NODULE
 ;;^UTILITY(U,$J,358.3,15527,2)
 ;;=^329934
 ;;^UTILITY(U,$J,358.3,15528,0)
 ;;=601.8^^95^945^19
 ;;^UTILITY(U,$J,358.3,15528,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15528,1,3,0)
 ;;=3^601.8
 ;;^UTILITY(U,$J,358.3,15528,1,4,0)
 ;;=4^PROSTATIS
 ;;^UTILITY(U,$J,358.3,15528,2)
 ;;=^270420
 ;;^UTILITY(U,$J,358.3,15529,0)
 ;;=791.0^^95^945^20
 ;;^UTILITY(U,$J,358.3,15529,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15529,1,3,0)
 ;;=3^791.0
 ;;^UTILITY(U,$J,358.3,15529,1,4,0)
 ;;=4^PROTEINURIA
 ;;^UTILITY(U,$J,358.3,15529,2)
 ;;=^99873
 ;;^UTILITY(U,$J,358.3,15530,0)
 ;;=590.80^^95^945^21
 ;;^UTILITY(U,$J,358.3,15530,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15530,1,3,0)
 ;;=3^590.80
 ;;^UTILITY(U,$J,358.3,15530,1,4,0)
 ;;=4^PYELONEPHRITIS NOS
 ;;^UTILITY(U,$J,358.3,15530,2)
 ;;=^101463
 ;;^UTILITY(U,$J,358.3,15531,0)
 ;;=592.0^^95^945^22
 ;;^UTILITY(U,$J,358.3,15531,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15531,1,3,0)
 ;;=3^592.0
 ;;^UTILITY(U,$J,358.3,15531,1,4,0)
 ;;=4^RENAL CALCULI
 ;;^UTILITY(U,$J,358.3,15531,2)
 ;;=^67056
 ;;^UTILITY(U,$J,358.3,15532,0)
 ;;=597.80^^95^945^23
 ;;^UTILITY(U,$J,358.3,15532,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15532,1,3,0)
 ;;=3^597.80
 ;;^UTILITY(U,$J,358.3,15532,1,4,0)
 ;;=4^URETHRITIS NOS
 ;;^UTILITY(U,$J,358.3,15532,2)
 ;;=^124214
 ;;^UTILITY(U,$J,358.3,15533,0)
 ;;=788.30^^95^945^25
 ;;^UTILITY(U,$J,358.3,15533,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15533,1,3,0)
 ;;=3^788.30
 ;;^UTILITY(U,$J,358.3,15533,1,4,0)
 ;;=4^URINARY INCONTINENCE
 ;;^UTILITY(U,$J,358.3,15533,2)
 ;;=^124400
 ;;^UTILITY(U,$J,358.3,15534,0)
 ;;=599.0^^95^945^24
 ;;^UTILITY(U,$J,358.3,15534,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15534,1,3,0)
 ;;=3^599.0
 ;;^UTILITY(U,$J,358.3,15534,1,4,0)
 ;;=4^URIN TRACT INFECTION NOS
 ;;^UTILITY(U,$J,358.3,15534,2)
 ;;=^124436
 ;;^UTILITY(U,$J,358.3,15535,0)
 ;;=585.1^^95^945^2
 ;;^UTILITY(U,$J,358.3,15535,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15535,1,3,0)
 ;;=3^585.1
 ;;^UTILITY(U,$J,358.3,15535,1,4,0)
 ;;=4^CHR KIDNEY DIS STAGE I
 ;;^UTILITY(U,$J,358.3,15535,2)
 ;;=^332807
 ;;^UTILITY(U,$J,358.3,15536,0)
 ;;=585.2^^95^945^3
 ;;^UTILITY(U,$J,358.3,15536,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15536,1,3,0)
 ;;=3^585.2
 ;;^UTILITY(U,$J,358.3,15536,1,4,0)
 ;;=4^CHR KIDNEY DIS STAGE II
 ;;^UTILITY(U,$J,358.3,15536,2)
 ;;=^332808
 ;;^UTILITY(U,$J,358.3,15537,0)
 ;;=585.3^^95^945^4
 ;;^UTILITY(U,$J,358.3,15537,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15537,1,3,0)
 ;;=3^585.3
 ;;^UTILITY(U,$J,358.3,15537,1,4,0)
 ;;=4^CHR KIDNEY DIS STAGE III
 ;;^UTILITY(U,$J,358.3,15537,2)
 ;;=^332809
 ;;^UTILITY(U,$J,358.3,15538,0)
 ;;=585.4^^95^945^5
 ;;^UTILITY(U,$J,358.3,15538,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15538,1,3,0)
 ;;=3^585.4
 ;;^UTILITY(U,$J,358.3,15538,1,4,0)
 ;;=4^CHR KIDNEY DIS STAGE IV
 ;;^UTILITY(U,$J,358.3,15538,2)
 ;;=^332810
 ;;^UTILITY(U,$J,358.3,15539,0)
 ;;=585.5^^95^945^6
